Clinical Trial Detail

NCT ID NCT02403193
Title Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Palobiofarma SL
Indications

non-small cell lung carcinoma

Therapies

PBF-509 + Spartalizumab

PBF-509

Age Groups: adult senior

No variant requirements are available.